NIH

NIH, Lacks family share genomic data of HeLa cells

Friday, August 9, 2013 01:17 PM

The National Institutes of Health has reached an understanding with the family of the late Henrietta Lacks to allow biomedical researchers controlled access to the whole genome data of cells derived from her tumor, commonly known as HeLa cells.

More... »

SAGE Therapeutics awarded NIH grant for Fragile X Syndrome

Thursday, August 1, 2013 10:30 AM

The NIH has granted SAGE Therapeutics, a neuroscience product-focused company creating novel medicines to treat central nervous system (CNS) disorders, an award potentially worth up to $10 million to support the company's development of a novel drug which could be used to treat anxiety and social deficits in patients with Fragile X Syndrome (FXS).

More... »

Boston Scientific, PFDN collaborate on Uterine Prolapse treatment

Friday, June 7, 2013 02:03 PM

Global medical technology company Boston Scientific provided a research and education grant of more than $1 million to the Pelvic Floor Disorders Network (PFDN) for the SUPeR clinical trial.  The SUPeR study will evaluate treatment outcomes of two different surgical options for women with uterine prolapse, a form of pelvic organ prolapse. PFDN is funded by the NIH.

More... »

Former FDA official Tim Cote joins Emmaus Medical as regulatory advisor

Friday, May 10, 2013 08:00 AM

Emmaus Medical, a specialty pharmaceutical and regenerative medicine company, has appointed Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the FDA, as its regulatory advisor. Cote will advise Emmaus on the regulatory pathway for the company's sickle cell disease treatment.

More... »

Lonza awarded NIH contract for research grade iPSCs

Monday, February 25, 2013 09:59 AM

The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza’s Walkersville, Md., facility a contract to generate induced pluripotent stem cells (iPSCs) for research purposes.  The contract is a three year agreement with a value up to $6.9 million dollars.                                      

More... »

NIH funds research to identify Parkinson's biomarkers

Wednesday, February 20, 2013 03:46 PM

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a three-year, $900,000 grant to the Center for Biomedical Imaging Statistics at Emory's Rollins School of Public Health. The grant will fund the center's biomarker research in Parkinson's disease to identify non-invasive imaging measures that can detect changes in brain function and biochemistry.

More... »

Lentigen receives Orphan Drug status for gene therapy for glioblastoma multiforme

Thursday, February 14, 2013 08:00 AM

Lentigen, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced that that the FDA has granted orphan drug status to LG631-CD34, P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells, for bone marrow protection in the treatment of glioblastoma multiforme.

More... »

FDA offers new guidance on developing drugs for Alzheimer's

Friday, February 8, 2013 11:47 AM

The FDA has issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable dementia.

More... »

Factor Bioscience awarded two NIH grants for Alzheimer's research

Monday, November 19, 2012 11:12 AM

The National Institutes of Health, through the National Center for Advancing Translational Sciences, has awarded Factor Bioscience, a developer of cell-based therapeutics and research tools, two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's disease.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »